Safety and Efficacy of Umbilical Cord Blood Serum Derived Extracellular Vesicles versus for Treatment of Androgenic Alopecia

Phase 1

• Conditions: Androgenic Alopecia.; Androgenic alopecia, unspecified; L64.9

• Registration Number: IRCT20221130056672N1
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 June 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Women and men with hereditary hormonal hair loss
Age 18 years and above and less than 50 years
The rate of hair loss in patients is Hamilton score 2 to 5 in men and Ludwig score 1 to 3 in women.
Complete consent of the patient to participate in the study

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The number of hair follicles using the Trichoscan device, the thickness of the hair follicle using the Trichoscan device. Timepoint: Before the start of the intervention, each treatment session is monthly for 4 months and also 6 months after the end of the treatment. Method of measurement: Findings from VISIOFACE and TES-TB (low hair type with X1 lens, hair density and scalp condition with X60Triple lens, hair diameter and PORE condition with KPL X150 lens and hair shaft surface condition with X700 lens.

Secondary Outcome Measures

Name	Time	Method
Safety and Efficacy. Timepoint: At the beginning of the intervention, monthly for 4 months, every one month, after 6 months. Method of measurement: Patient's history, examination, hair diameter, number of hair per surface unit, patient's satisfaction level.